PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
February 28, 2026BMC PediatricsOpen Access

Sustained remission of post-Fontan protein-losing enteropathy achieved by combination therapy with high-dose spironolactone and the somatostatin analogue octreotide: a case report

View Full Paper
Ask AI
Bookmark
Share

Authors

ESEmiko SuzukiKJKeisuke JimboHFHideo Fukunaga

Discussion

Loading...

Member takes

Overview

A case report demonstrates remission of protein-losing enteropathy in a child, highlighting effective treatment options.

Key Points

  • The aim is to evaluate the effectiveness of high-dose spironolactone combined with octreotide in treating post-Fontan protein-losing enteropathy.
  • Descriptive case report of a 5-year-old girl with post-Fontan protein-losing enteropathy.
  • Initial treatment with standard-dose spironolactone and octreotide with minimal improvement.
  • Escalation of spironolactone to high-dose and transitioning octreotide to intramuscular administration.
  • Long-term follow-up to assess remission and medication tapering.
  • High-dose spironolactone led to progressive resolution of hypoproteinemia.
  • Octreotide was tapered successfully after achieving sustained remission.
  • The patient maintained remission for over 1.5 years after octreotide withdrawal.
  • Central venous pressure and fecal α1-antitrypsin levels were effectively managed.

Cite This Study

Suzuki et al. (2026) studied this question.

synapsesocial.com/papers/69a287e20a974eb0d3c03c54https://doi.org/10.1186/s12887-026-06671-3
View Full Paper
Ask AI
Bookmark
Share